Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Structural and functional insights into the Rcs phosphorelay.

bioRxiv : the preprint server for biology·2026

Same author

16S ribosomal RNA modification drives transcript-specific translation efficiency.

bioRxiv : the preprint server for biology·2026

Same author

Large Language Models Meet Biomedical Knowledge Graphs for Mechanistically Grounded Therapeutic Prioritization.

ArXiv·2026

Same author

Use of yttrium-90 radioembolization to control liver metastases in pancreatic acinar cell carcinoma and pancreatoblastoma: Two case reports.

World journal of gastroenterology·2026

Same author

A quorum-sensing molecule from <i>Pseudomonas aeruginosa</i> induces defensive multicellularity in a coinfecting pathogen.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

NsrR Represses σ<sup>E</sup>-Dependent Small RNAs and Interacts with RpoE via a Noncanonical Mechanism in <i>Escherichia coli</i>.

International journal of molecular sciences·2025

Search research articles

Related Experiment Video

Updated: Dec 16, 2025

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.

Brendan L Hagerty^1,2, Guillaume J Pegna^1,3, Jian Xu¹

¹Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.

|July 2, 2020

Summary

Mesothelin (MSLN)-targeted immunotoxins show promise against solid tumors like mesothelioma. Challenges include anti-drug antibodies and toxicity, requiring further research for enhanced anti-cancer therapy.

Keywords:

immunotoxin mesothelin mesothelioma pancreatic adenocarcinoma

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Dec 16, 2025

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

Oncology
Immunotherapy
Molecular Biology

Background:

Mesothelin (MSLN) is a cell surface glycoprotein expressed on serosal surfaces and in various solid tumors, including mesothelioma and pancreatic adenocarcinoma.
This expression profile makes MSLN a promising target for novel anti-neoplastic therapies.

Purpose of the Study:

To review pre-clinical and clinical data on MSLN-targeted recombinant immunotoxins (iToxs).
To identify challenges and future research directions for enhancing the efficacy of MSLN-targeted iToxs.

Main Methods:

Review of existing pre-clinical studies on MSLN-targeted iToxs.
Analysis of clinical trial data for MSLN-targeted iToxs (SS1P and LMB-100).

Main Results:

Pre-clinical studies demonstrate significant activity of MSLN-targeted iToxs against solid tumors.
Clinical trials show promising results but are challenged by anti-drug antibody (ADA) formation and on-target, off-tumor toxicities (serositis, capillary leak syndrome).

Conclusions:

MSLN-targeted immunotoxins represent a viable therapeutic strategy for solid tumors.
Overcoming ADA formation and dose-limiting toxicities is crucial for improving therapeutic impact and requires further research.